Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | BRS3 | P32247 | 1/20 | 0.48 |
| ▸ | CHKA | P35790 | 6/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11923149 | 0.98 | ALDH1A1 (0.48) | ALDH1A1MAPTKDM4EHTTALOX15 | |
| SCHEMBL8352110 | 0.83 | ALDH1A1 (0.58) | ALDH1A1MAPTKDM4EL3MBTL1NPC1 | |
| SCHEMBL9969466 | 0.83 | MAPT (0.50) | ALDH1A1MAPTKDM4EHTTALOX15 | |
| SCHEMBL13215562 | 0.83 | BRS3 (0.57) | ALDH1A1MAPTKDM4EHTTALOX15 | |
| SCHEMBL21933940 | 0.81 | ESR1 (0.42) | ALDH1A1MAPTKDM4EHTTPOLB | |
| SCHEMBL8351039 | 0.79 | KDM4E (0.57) | ALDH1A1MAPTKDM4EGAAESR1 | |
| SCHEMBL10190904 | 0.79 | PRMT6 (0.62) | ALDH1A1MAPTKDM4EL3MBTL1MEN1 | |
| SCHEMBL18618234 | 0.78 | CHKA (0.56) | ALDH1A1MAPTKDM4EHTTALOX15 | |
| SCHEMBL300433 | 0.78 | CHKA (0.56) | ALDH1A1MAPTKDM4EHTTALOX15 | |
| SCHEMBL20306322 | 0.78 | POLB (0.56) | ALDH1A1MAPTKDM4EHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20210179564-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20190071404-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-03-07 | — | — | US | disclosed |
| US-10183015-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-01 | — | — | US | disclosed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-8435978-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-7674828-B2 | Urea antagonists of P2Y1receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-09 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY2 | ALDH1A1 1978/4885MAPT 3475/4885KDM4E 3641/4885 |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | ALDH1A1 1535/4885MAPT 2195/4885KDM4E 3171/4885 |
| US-20190071404-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | ALDH1A1 1808/4885MAPT 2002/4885KDM4E 1864/4885 |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | ALDH1A1 1535/4885MAPT 2195/4885KDM4E 3171/4885 |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | SULT2A1, STS, SULT1A1 | ALDH1A1 1535/4885MAPT 2195/4885KDM4E 3171/4885 |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | ALDH1A1 1808/4885MAPT 2002/4885KDM4E 1864/4885 |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | ALDH1A1 1901/4885MAPT 4649/4885KDM4E 1425/4885 |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | LIPC, CPT1A, FABP1 | ALDH1A1 779/4885MAPT 4172/4885KDM4E 2233/4885 |
| US-20210179564-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | ALDH1A1 1808/4885MAPT 2002/4885KDM4E 1864/4885 |
| US-10183015-B2 | Heterocyclic compounds and methods of use | LIPC, CPT1A, FABP1 | ALDH1A1 779/4885MAPT 4172/4885KDM4E 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.